Edition:
United States

People: Amgen Inc (AMGN.O)

AMGN.O on Nasdaq

181.90USD
16 Oct 2017
Change (% chg)

$-1.11 (-0.61%)
Prev Close
$183.01
Open
$182.96
Day's High
$184.20
Day's Low
$181.20
Volume
2,211,464
Avg. Vol
2,813,034
52-wk High
$191.10
52-wk Low
$133.64

Jacks, Tyler 

Dr. Tyler Jacks Ph.D., is an Independent Director of Amgen Inc. Tyler Jacks joined the faculty of Massachusetts Institute of Technology, or MIT, in 1992 and is currently the David H. Koch Professor of Biology and director of the David H. Koch Institute for Integrative Cancer Research, which brings together biologists and engineers to improve detection, diagnosis and treatment of cancer, a position he has held since 2007. Dr. Jacks has been an investigator with the Howard Hughes Medical Institute, a nonprofit medical research organization, since 1994. Dr. Jacks has been a director of Thermo Fisher Scientific, Inc., a life sciences supply company, since May 2009, and serves on its Strategy and Finance Committee and scientific advisory board. In 2006, he co-founded T2 Biosystems, Inc., a biotechnology company, and served on its scientific advisory board until 2013. Dr. Jacks has been a consultant scientific advisor to Epizyme, Inc., a biopharmaceutical company, since 2007, and has served on the scientific advisory board of SQZ Biotech, a privately-held biotechnology company, since 2015. Dr. Jacks served on the scientific advisory board of Aveo Pharmaceuticals Inc., a biopharmaceutical company, from 2001 until 2013. In 2015, Dr. Jacks founded Dragonfly Therapeutics, Inc. (formerly known as Equipoise Therapeutics), a privately-held biopharmaceutical company, in 2015 and serves as co-Chair of its scientific advisory board. He was appointed to the National Cancer Advisory Board, which advises and assists the Director of the National Cancer Institute with respect to the National Cancer Program, in October 2011. In April 2016, Dr. Jacks was named to a blue ribbon panel of scientists and advisors established as a working group of the National Cancer Advisory Board and served as co-Chair advising the Cancer MoonshotSM Task Force.

Basic Compensation

Total Annual Compensation, USD 119,000
Restricted Stock Awards, USD 199,972
Long-Term Incentive Plans, USD --
All Other, USD 18,865
Fiscal Year Total, USD 337,837

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Robert Bradway

16,850,000

David Meline

6,218,460

Sean Harper

6,213,040

Anthony Hooper

6,965,180

Brian McNamee

--

Esteban Santos

--
As Of  30 Dec 2016